Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

Delayed Quote. Delayed  - 09/30 10:14:59 pm
79.12 USD   +1.62%
09/27 GILEAD SCIENCES : and the World Health Organization Announce Five-Ye..
09/27 NASDAQ 100 MOVE : Gild, nclh
09/22 ABZENA : Says Gilead Halts Ulcerative Colitis Trials For GS-5745
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Gilead Sciences, Inc. : U.S. FDA Grants Priority Review for Truvada? for Reducing the Risk of Acquiring HIV Infection

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/14/2012 | 01:38am CEST

FOSTER CITY, Calif.--(BUSINESS WIRE)--Feb. 13, 2012-- Gilead Sciences, Inc. (Nasdaq:GILD) announced today that the U.S. Food and Drug Administration (FDA) has accepted the supplemental New Drug Application (sNDA) and granted a six-month Priority Review for once-daily Truvada® (emtricitabine/tenofovir disoproxil fumarate) for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection among uninfected adults. Truvada was approved by the FDA in 2004 for the treatment of HIV-1 infection and is currently the most-prescribed antiretroviral treatment in the United States.

The FDA grants priority review status to drug candidates that provide major advances in treatment or provide a treatment where no adequate therapy exists. Gilead submitted the Truvada for PrEP sNDA on December 15, 2011. The FDA has set a target review date for Truvada for PrEP under the Prescription Drug User Fee Act (PDUFA) of June 15, 2012. The agency has also indicated that Truvada for PrEP will be discussed at the FDA Antiviral Drugs Advisory Committee meeting scheduled in May.

If the sNDA is approved, Truvada would be the first agent indicated for uninfected individuals to reduce the risk of acquiring HIV. The sNDA is based on the results of two large placebo-controlled trials of Truvada as PrEP sponsored by the U.S. National Institutes of Health and the University of Washington. Several other clinical studies support the use of Truvada for HIV risk reduction.

Truvada is not currently indicated to reduce the risk of HIV infection.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.

Forward-Looking Statement

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including the risk that the FDA may not approve Truvada for HIV-1 risk reduction, and any approval, if granted, may have significant limitations on its use. Additionally, even if approved, physicians may be reluctant to prescribe the product for HIV risk reduction, and payers may be reluctant to approve or provide reimbursement for the product for HIV risk reduction. As a result, there may not be significant use of Truvada as a risk reduction tool. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead's Quarterly Report on Form 10-Q for the quarter ended September 30, 2011, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

U.S. . www.Truvada.com

Truvada is a registered trademark of Gilead Sciences, Inc.

For more information on Gilead Sciences, please visit the company's website at or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Source: Gilead Sciences, Inc.

Gilead Sciences, Inc.
Patrick O'Brien, 650-522-1936 (Investors)
Cara Miller, 650-522-1616 (Media)

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on GILEAD SCIENCES, INC.
09/29 GILEAD SCIENCES : Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerat..
09/27 GILEAD SCIENCES : and the World Health Organization Announce Five-Year Visceral ..
09/27 NASDAQ 100 MOVERS : Gild, nclh
09/22 ABZENA : Says Gilead Halts Ulcerative Colitis Trials For GS-5745
09/21 GILEAD SCIENCES : Terminates Phase 2/3 Study of GS-5745 in Patients With Ulcerat..
09/21DJGILEAD SCIENCES : Halts Test of Bowel Disease Treatment
09/20 GILEAD SCIENCES INC : Entry into a Material Definitive Agreement, Creation of a ..
09/20 STOCKS HIGHLIGHTS : Gilead Sciences, Inc. Wellcare Health Plans, Inc.
09/16 GILEAD SCIENCES : Prices $5 Billion of Senior Unsecured Notes
09/15 GILEAD SCIENCES : to Present at Three Upcoming Investor Conferences in September
More news
Sector news : Bio Therapeutic Drugs
09/29DJARROWHEAD PHARMACEUTICALS : Amgen, Arrowhead Pharma Agree to Cardiovascular Coll..
09/27DJAMGEN : Myeloma Treatment Study Fails to Meet Primary Endpoint
09/26DJSANOFI : FDA Accepts Sanofi's, Regeneron's Dermatitis Treatment for Priority Rev..
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- 2nd Update
09/23DJAMGEN : FDA Approves Amgen's Biosimilar Version of Humira -- Update
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
09/30 GILEAD'S CORPORATE CULTURE : Fair Game For Commentators?
09/30 AMGEN GETS BUSY; MANY NEWS ITEMS : Anything Good Yet?
09/30 Trouble For Stocks Today - Month And Quarter End Is Conducive To Trouble
09/30 Healthcare ratings roundup - upgrades/downgrades
09/29 NONALCOHOLIC STEATOHEPATITIS (NASH) : What's The Market Opportunity And Who Are ..
Advertisement
Financials ($)
Sales 2016 30 469 M
EBIT 2016 20 160 M
Net income 2016 14 539 M
Debt 2016 5 504 M
Yield 2016 2,34%
P/E ratio 2016 7,45
P/E ratio 2017 7,13
EV / Sales 2016 3,61x
EV / Sales 2017 3,57x
Capitalization 104 411 M
More Financials
Chart GILEAD SCIENCES, INC.
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 105 $
Spread / Average Target 33%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-21.81%104 411
AMGEN, INC.2.76%124 834
CELGENE CORPORATION-12.72%81 023
REGENERON PHARMACEUTIC..-25.95%42 330
VERTEX PHARMACEUTICALS..-30.69%21 609
ACTELION LTD20.63%18 653
More Results